PMID- 33396800 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210111 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 1 DP - 2020 Dec 30 TI - Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. LID - 10.3390/jcm10010105 [doi] LID - 105 AB - The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). FAU - Akizuki, Keiichi AU - Akizuki K AUID- ORCID: 0000-0003-0031-3456 AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Matsuoka, Hitoshi AU - Matsuoka H AD - Department of Internal Medicine, Koga General Hospital, 1749-1 Sudaki, Ikeuchi Machi, Miyazaki 880-0041, Japan. FAU - Toyama, Takanori AU - Toyama T AD - Department of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital, 2-1-10 Shinkouji, Nobeoka 882-0835, Japan. FAU - Kamiunten, Ayako AU - Kamiunten A AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Sekine, Masaaki AU - Sekine M AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Shide, Kotaro AU - Shide K AUID- ORCID: 0000-0002-0046-3254 AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Kameda, Takuro AU - Kameda T AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Kawano, Noriaki AU - Kawano N AD - Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, 5-30 Kitatakamatsu, Miyazaki 880-8510, Japan. FAU - Maeda, Kouichi AU - Maeda K AD - Department of Internal Medicine, Miyakonojo Medical Center, 5033-1 Iwayoshi-cho, Miyakonojo 880-8510, Japan. FAU - Takeuchi, Masanori AU - Takeuchi M AD - Department of Internal Medicine, Koga General Hospital, 1749-1 Sudaki, Ikeuchi Machi, Miyazaki 880-0041, Japan. FAU - Kawano, Hiroshi AU - Kawano H AD - Department of Internal Medicine, Koga General Hospital, 1749-1 Sudaki, Ikeuchi Machi, Miyazaki 880-0041, Japan. FAU - Sato, Seiichi AU - Sato S AD - Fujimoto General Hospital, 17-1 Hayasuzumachi, Miyakonojo 885-0055, Japan. FAU - Ishizaki, Junzo AU - Ishizaki J AD - Department of Internal Medicine, Miyazaki Aisenkai Nichinan Hospital, 3649-2 Kazeta, Nichinan 887-0034, Japan. FAU - Tahira, Yuki AU - Tahira Y AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Shimoda, Haruko AU - Shimoda H AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Hidaka, Tomonori AU - Hidaka T AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Yamashita, Kiyoshi AU - Yamashita K AUID- ORCID: 0000-0002-0194-2046 AD - Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, 5-30 Kitatakamatsu, Miyazaki 880-8510, Japan. FAU - Kubuki, Yoko AU - Kubuki Y AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. FAU - Shimoda, Kazuya AU - Shimoda K AD - Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. LA - eng PT - Journal Article DEP - 20201230 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC7795356 OTO - NOTNLM OT - international staging system OT - multiple myeloma OT - prognostic factors OT - real-world outcomes COIS- K Shide received Grant-in-Aid for Clinical Research from University of Miyazaki Hospital for this article. No other author has reported a potential conflict of interest relevant to this article. EDAT- 2021/01/06 06:00 MHDA- 2021/01/06 06:01 PMCR- 2020/12/30 CRDT- 2021/01/05 01:17 PHST- 2020/11/04 00:00 [received] PHST- 2020/12/27 00:00 [revised] PHST- 2020/12/28 00:00 [accepted] PHST- 2021/01/05 01:17 [entrez] PHST- 2021/01/06 06:00 [pubmed] PHST- 2021/01/06 06:01 [medline] PHST- 2020/12/30 00:00 [pmc-release] AID - jcm10010105 [pii] AID - jcm-10-00105 [pii] AID - 10.3390/jcm10010105 [doi] PST - epublish SO - J Clin Med. 2020 Dec 30;10(1):105. doi: 10.3390/jcm10010105.